Stephen P. DeFalco
Known title: DirectorCIK: 0001666964
Associated companies
Transaction History
| SENS | ▲ Buy | Grant | 9,852 | $0 | 5/20/2026 | View on chart |
| SENS | ▲ Buy | Grant | 111,386 | $0 | 5/23/2025 | View on chart |
| SENS | ▲ Buy | Grant | 236,344 | $0 | 5/22/2024 | View on chart |
| SENS | ▲ Buy | Grant | 42,410 | $24K | 1/2/2024 | View on chart |
| SENS | ▲ Buy | Grant | 42,410 | $24K | 10/2/2023 | View on chart |
| SENS | ▲ Buy | Grant | 29,972 | $24K | 7/3/2023 | View on chart |
| SENS | ▲ Buy | Grant | 147,948 | $0 | 5/17/2023 | View on chart |
| SENS | ▲ Buy | Grant | 39,240 | $25K | 4/3/2023 | View on chart |
| SENS | ▲ Buy | Grant | 24,271 | $25K | 1/3/2023 | View on chart |
| SENS | ▲ Buy | Grant | 19,083 | $0 | 10/3/2022 | View on chart |
| SENS | ▲ Buy | Grant | 24,509 | $0 | 7/1/2022 | View on chart |
| SENS | ▲ Buy | Grant | 99,557 | $0 | 5/26/2022 | View on chart |
| SENS | ▲ Buy | Grant | 12,886 | $25K | 4/1/2022 | View on chart |
| SENS | ▲ Buy | Grant | 9,090 | $25K | 1/3/2022 | View on chart |
| SENS | ▲ Buy | Grant | 7,246 | $25K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.